Description

Ensitrelvir Fumarate CAS NO 2757470-18-9 is a high-purity active pharmaceutical ingredient (API) and a key intermediate in antiviral research and development. This compound is of significant commercial and scientific interest as a potent 3CL protease inhibitor, targeting the main protease of SARS-CoV-2. It is primarily required by pharmaceutical manufacturers, contract research organizations (CROs), and academic institutions engaged in the development of next-generation antiviral therapeutics and clinical studies.

Application

• Pharmaceutical API: Serves as the active pharmaceutical ingredient in the formulation of antiviral medications.
• Antiviral Drug Development: A critical intermediate for the research and synthesis of novel SARS-CoV-2 3CL protease inhibitors.
• Clinical Trial Material: Used in the production of drug substances for Phase I-III clinical trials investigating COVID-19 treatments.
• Biochemical Research: Employed as a reference standard and tool compound in virology and protease inhibition studies.
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for scale-up and commercial production.
• Preclinical Studies: Utilized in in-vitro and in-vivo models to evaluate antiviral efficacy and pharmacokinetics.

Basic Information

Item	Details
Product Name	Ensitrelvir Fumarate
CAS No.	2757470-18-9
Molecular Formula	C26H19F2N5O5 • C4H4O4
Molecular Weight	Contact for details
Synonyms	Ensitrelvir Fumarate Salt; S-217622 Fumarate; Xocova Intermediate; SARS-CoV-2 3CL Protease Inhibitor S-217622 Fumarate; (1R,2S,5S)-N-[(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide Fumarate; 3CLpro Inhibitor S-217622 Fumarate
EINECS	Contact for details

Quality Control

Our Ensitrelvir Fumarate is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity, chiral purity determination, and residual solvent analysis, to ensure it meets stringent pharmaceutical-grade specifications. Certificates of Analysis (COA) with full traceability are provided and can be tailored to support regulatory filings for clinical or commercial use.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept under dry, inert conditions to maintain stability and potency.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC/IR)	Conforms to reference standard
Assay (HPLC)	≥98.0%
Chiral Purity (HPLC)	≥99.0%
Related Substances (HPLC)	Total impurities ≤2.0%
Residual Solvents (GC)	Complies with ICH Q3C
Water Content (KF)	≤1.0%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.